Abemaciclib plus endocrine therapy in HR-positive, HER2-negative high-risk early breast cancer: efficacy in nodal subgroups.
Cortes J, Johnston SRD, Martin M, Tolaney SM et al. • ESMO open
(2026)
PMC
PMC Public Access (View-Only)
DOI:
10.1016/j.esmoop.2026.108549
PMC: PMC13654022